Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12950MR)

This product GTTS-WQ12950MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF12A gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_016639.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51330
UniProt ID Q9NP84
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12950MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9436MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ541MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ3090MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ14339MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ15064MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SSS-23
GTTS-WQ1954MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ4452MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ3704MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 2287409
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW